The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis.
Comorbidities
Drug-drug interactions
Genitourinary system diseases
Multiple system atrophy
Polypharmacy
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
14 Feb 2024
14 Feb 2024
Historique:
received:
01
12
2023
accepted:
16
01
2024
medline:
14
2
2024
pubmed:
14
2
2024
entrez:
14
2
2024
Statut:
aheadofprint
Résumé
Multiple system atrophy (MSA) is a complex and fatal neurodegenerative movement disorder. Understanding the comorbidities and drug therapy is crucial for MSA patients' safety and management. To investigate the pattern of comorbidities and aspects of drug therapy in MSA patients. Cross-sectional data of MSA patients according to Gilman et al. (2008) diagnostic criteria and control patients without neurodegenerative diseases (non-ND) were collected from German, multicenter cohorts. The prevalence of comorbidities according to WHO ICD-10 classification and drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were identified using AiDKlinik®. The analysis included 254 MSA and 363 age- and sex-matched non-ND control patients. MSA patients exhibited a significantly higher burden of comorbidities, in particular diseases of the genitourinary system. Also, more medications were prescribed MSA patients, resulting in a higher prevalence of polypharmacy. Importantly, the risk of potential drug-drug interactions, including severe interactions and contraindicated combinations, was elevated in MSA patients. When comparing MSA-P and MSA-C subtypes, MSA-P patients suffered more frequently from diseases of the genitourinary system and diseases of the musculoskeletal system and connective tissue. MSA patients face a substantial burden of comorbidities, notably in the genitourinary system. This, coupled with increased polypharmacy and potential drug interactions, highlights the complexity of managing MSA patients. Clinicians should carefully consider these factors when devising treatment strategies for MSA patients.
Sections du résumé
BACKGROUND
BACKGROUND
Multiple system atrophy (MSA) is a complex and fatal neurodegenerative movement disorder. Understanding the comorbidities and drug therapy is crucial for MSA patients' safety and management.
OBJECTIVES
OBJECTIVE
To investigate the pattern of comorbidities and aspects of drug therapy in MSA patients.
METHODS
METHODS
Cross-sectional data of MSA patients according to Gilman et al. (2008) diagnostic criteria and control patients without neurodegenerative diseases (non-ND) were collected from German, multicenter cohorts. The prevalence of comorbidities according to WHO ICD-10 classification and drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were identified using AiDKlinik®.
RESULTS
RESULTS
The analysis included 254 MSA and 363 age- and sex-matched non-ND control patients. MSA patients exhibited a significantly higher burden of comorbidities, in particular diseases of the genitourinary system. Also, more medications were prescribed MSA patients, resulting in a higher prevalence of polypharmacy. Importantly, the risk of potential drug-drug interactions, including severe interactions and contraindicated combinations, was elevated in MSA patients. When comparing MSA-P and MSA-C subtypes, MSA-P patients suffered more frequently from diseases of the genitourinary system and diseases of the musculoskeletal system and connective tissue.
CONCLUSIONS
CONCLUSIONS
MSA patients face a substantial burden of comorbidities, notably in the genitourinary system. This, coupled with increased polypharmacy and potential drug interactions, highlights the complexity of managing MSA patients. Clinicians should carefully consider these factors when devising treatment strategies for MSA patients.
Identifiants
pubmed: 38353748
doi: 10.1007/s00415-024-12207-5
pii: 10.1007/s00415-024-12207-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Sylvia Maaß
(S)
Madeleine Schubert
(M)
Armin Giese
(A)
Wolfgang H Oertel
(WH)
Werner Poewe
(W)
Claudia Trenkwalder
(C)
Gregor K Wenning
(GK)
Ulrich Mansmann
(U)
Martin Südmeyer
(M)
Karla Eggert
(K)
Brit Mollenhauer
(B)
Axel Lipp
(A)
Matthias Löhle
(M)
Joseph Classen
(J)
Alexander Münchau
(A)
Jan Kassubek
(J)
Daniela Berg
(D)
Silvia Egert-Schwender
(S)
Cornelia Eberhardt
(C)
Friedemann Paul
(F)
Kai Bötzel
(K)
Birgit Ertl-Wagner
(B)
Hans-Jürgen Huppertz
(HJ)
Ingrid Ricard
(I)
Elisabeth André
(E)
Christiane Blankenstein
(C)
Monica Canelo
(M)
Marco Düring
(M)
Jens Ebentheuer
(J)
Christopher Fricke
(C)
Alexander Gerbes
(A)
Stefan Groiss
(S)
Christian Hartmann
(C)
Thomas Kirchner
(T)
Daniel Kroneberg
(D)
Martin Kunz
(M)
Stefan Lorenzl
(S)
Alexia Moldovan
(A)
Anna Noda
(A)
Heidi Pape
(H)
Gesine Respondek
(G)
Eva Schäffer
(E)
Alfons Schnitzler
(A)
Walter Schulz-Schaeffer
(W)
Johannes Schwarz
(J)
Cornelia Skowronek
(C)
Alexander Storch
(A)
Vera Tadic
(V)
Dávid Vadász
(D)
Benno Zimmermann
(B)
Martina Schneider
(M)
Informations de copyright
© 2024. The Author(s).
Références
Krismer F, Wenning GK (2017) Multiple system atrophy: insights into a rare and debilitating movement disorder. Nat Rev Neurol 13:232–243
doi: 10.1038/nrneurol.2017.26
pubmed: 28303913
Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676
doi: 10.1212/01.wnl.0000324625.00404.15
pubmed: 18725592
pmcid: 2676993
Poewe W, Stankovic I, Halliday G et al (2022) Multiple system atrophy. Nat Rev Dis Primers 8:56
doi: 10.1038/s41572-022-00382-6
pubmed: 36008429
Vichayanrat E, Valerio F, Koay S et al (2022) Diagnosing premotor multiple system atrophy: natural history and autonomic testing in an autopsy-confirmed cohort. Neurology 99:e1168–e1177
doi: 10.1212/WNL.0000000000200861
pubmed: 35790426
pmcid: 9536739
Matsushima M, Yabe I, Sakushima K et al (2021) Multiple system atrophy in Hokkaido, Japan: a prospective registry study of natural history and symptom assessment scales followed for 5 years. BMJ Open 11:e045100
doi: 10.1136/bmjopen-2020-045100
pubmed: 33558361
pmcid: 7871682
Low PA, Reich SG, Jankovic J et al (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14:710–719
doi: 10.1016/S1474-4422(15)00058-7
pubmed: 26025783
pmcid: 4472464
Jecmenica-Lukic M, Petrovic IN, Pekmezovic T, Kostic VS (2014) Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study. J Neurol 261:1575–1583
doi: 10.1007/s00415-014-7384-x
pubmed: 24888315
Gijsen R, Hoeymans N, Schellevis FG et al (2001) Causes and consequences of comorbidity: a review. J Clin Epidemiol 54:661–674
doi: 10.1016/S0895-4356(00)00363-2
pubmed: 11438406
Pazan F, Wehling M (2021) Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med 12:443–452
doi: 10.1007/s41999-021-00479-3
pubmed: 33694123
pmcid: 8149355
Levin J, Maaß S, Schuberth M et al (2019) Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 18:724–735
doi: 10.1016/S1474-4422(19)30141-3
pubmed: 31278067
Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide. Mov Disord Clin Pract 7:343–345
doi: 10.1002/mdc3.12921
pubmed: 32258239
pmcid: 7111582
Papapetropoulos S, Tuchman A, Laufer D et al (2007) Causes of death in multiple system atrophy. J Neurol Neurosurg Psychiatry 78:327–329
doi: 10.1136/jnnp.2006.103929
pubmed: 17308296
pmcid: 2117630
Zhang L, Cao B, Zou Y et al (2018) Causes of death in Chinese patients with multiple system atrophy. Aging Dis 9:102–108
doi: 10.14336/AD.2017.0711
pubmed: 29392085
pmcid: 5772848
Reynolds WS, Suskind AM, Anger JT et al (2022) Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: multi-institutional collaboration from the SUFU research network. Neurourol Urodyn 41:662–671
doi: 10.1002/nau.24871
pubmed: 35019167
pmcid: 8891079
Sundén F, Håkansson L, Ljunggren E, Wullt B (2010) Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol 184:179–185
doi: 10.1016/j.juro.2010.03.024
pubmed: 20483149
Wenning GK, Stankovic I, Vignatelli L et al (2022) The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord 37:1131–1148
doi: 10.1002/mds.29005
pubmed: 35445419
pmcid: 9321158
Ananthavarathan P, Patel B, Peeros S et al (2023) Neurological update: non-motor symptoms in atypical parkinsonian syndromes. J Neurol. https://doi.org/10.1007/s00415-023-11807-x
doi: 10.1007/s00415-023-11807-x
pubmed: 37316556
pmcid: 10827884
Chen B, Yang W, Luo Y et al (2023) Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions. J Neurol. https://doi.org/10.1007/s00415-023-11876-y
doi: 10.1007/s00415-023-11876-y
pubmed: 38063869
pmcid: 10267003
Camargo Maluf F, Feder D, de Siqueira A, Carvalho A (2019) Analysis of the relationship between type II diabetes mellitus and Parkinson’s disease: a systematic review. Parkinsons Dis 2019:4951379
pubmed: 31871617
pmcid: 6906831
Chohan H, Senkevich K, Patel RK et al (2021) Type 2 diabetes as a determinant of Parkinson’s disease risk and progression. Mov Disord 36:1420–1429
doi: 10.1002/mds.28551
pubmed: 33682937
pmcid: 9017318
Horvath I, Wittung-Stafshede P (2016) Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson’s disease. Proc Natl Acad Sci U S A 113:12473–12477
doi: 10.1073/pnas.1610371113
pubmed: 27791129
pmcid: 5098634
Shahnawaz M, Mukherjee A, Pritzkow S et al (2020) Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 578:273–277
doi: 10.1038/s41586-020-1984-7
pubmed: 32025029
pmcid: 7066875
Rizzo G, Copetti M, Arcuti S et al (2016) Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86:566–576
doi: 10.1212/WNL.0000000000002350
pubmed: 26764028
Miki Y, Tsushima E, Foti SC et al (2021) Identification of multiple system atrophy mimicking Parkinson’s disease or progressive supranuclear palsy. Brain 144:1138–1151
doi: 10.1093/brain/awab017
pubmed: 33822892
pmcid: 8310424